hydroxyproline has been researched along with mangiferin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pal, PB; Sil, PC; Sinha, K | 1 |
| Anand, M; Choudhury, S; Prabhu, SN; Shukla, A; Singh, R; Yadav, VP | 1 |
2 other study(ies) available for hydroxyproline and mangiferin
| Article | Year |
|---|---|
Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycation End Products, Advanced; Hydroxyproline; Hyperglycemia; Kidney Glomerulus; Male; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Oxidative Stress; Protein Kinase C; Rats; Rats, Wistar; Reactive Oxygen Species; Signal Transduction; Streptozocin; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Xanthine Oxidase; Xanthones | 2014 |
IL1β/ TNFα/COX-2/VEGF axis responsible for effective healing potential of C-glucoside xanthone (mangiferin) based ointment in immunocompromised rats.
Topics: Animals; Cyclooxygenase 2; Glucosides; Hydroxyproline; Interleukin-1beta; Ointments; Rats; Skin; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xanthones | 2022 |